Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Amendments Act Implementation Faces Delay; Agency To Miss Deadlines

Executive Summary

FDA is expected to miss a spate of implementation deadlines for provisions of the FDA Amendments Act as the law approaches its first anniversary

You may also be interested in...



FDA Priority Review Voucher Guidance Coming: Incentive Has Low Visibility

FDA is planning a public meeting to discuss the new priority review voucher system to begin implementing the new program

FDA Priority Review Voucher Guidance Coming: Incentive Has Low Visibility

FDA is planning a public meeting to discuss the new priority review voucher system to begin implementing the new program

FDA Amendments Act’s One-Year Anniversary: For Better Or Worse

At the one-year anniversary of the FDA Amendments Act, the agency's record is mixed in meeting its increased responsibilities and authorities the law requires

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS050091

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel